Barclays
LABP

Barclays’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Barclays’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-76
Closed -$1K – 5399
2022
Q1 		$1K Buy
+76
New +$1.93K ﹤0.01% 4862

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's LABP Position: Q2 2022 in Review

Barclays sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2022, closing a stake of 76 shares — an estimated $1K sold.

Barclays first reported a position in LABP in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 34 funds tracked by Wall St. Rank hold LABP as of Q2 2022.

  • Barclays reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 76 Landos Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $1K.
  • Barclays first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Barclays's Landos Biopharma, Inc. Common Stock position peaked at $1K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.